Perigon Wealth Management LLC Boosts Stake in Novo Nordisk A/S $NVO

Perigon Wealth Management LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 316.5% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,375 shares of the company’s stock after purchasing an additional 36,761 shares during the period. Perigon Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,684,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Kingstone Capital Partners Texas LLC lifted its position in shares of Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock valued at $690,560,000 after buying an additional 10,001,898 shares in the last quarter. Amundi raised its stake in Novo Nordisk A/S by 49.1% during the 1st quarter. Amundi now owns 4,938,507 shares of the company’s stock worth $331,576,000 after acquiring an additional 1,627,051 shares during the period. Bank of Montreal Can lifted its holdings in Novo Nordisk A/S by 101.4% during the second quarter. Bank of Montreal Can now owns 2,475,300 shares of the company’s stock valued at $170,845,000 after purchasing an additional 1,246,467 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 15,919.9% in the first quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company’s stock worth $72,523,000 after purchasing an additional 1,038,137 shares during the period. Finally, DAVENPORT & Co LLC increased its stake in shares of Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after purchasing an additional 935,468 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approved Novo’s oral Wegovy pill, broadening how patients can take its leading GLP‑1 weight‑loss therapy and opening a large new addressable market for oral treatment forms. Novo Nordisk’s Wegovy Pill Wins U.S. Approval
• Positive Sentiment: Early analyst/coverage pieces highlight strong efficacy data for the oral Wegovy (noted mean weight loss and high share of patients >20% weight loss), positioning the pill as a potential market‑share and growth driver versus rivals. Novo Nordisk: Oral Weight-Loss To The Rescue
• Positive Sentiment: Market reaction: some outlets report a strong short‑term rally (double‑digit intraday moves in recent sessions) after the pill approval, reflecting renewed investor optimism about sales upside. Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK
• Positive Sentiment: Coverage suggests the FDA nod could lift healthcare ETFs and related peers as the oral GLP‑1 opportunity reshapes the sector, a tailwind for investor flows into NVO and peers. The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
• Positive Sentiment: Reports say Novo is pricing the oral Wegovy to undercut Eli Lilly in direct‑to‑consumer channels — a deliberate share‑capture strategy that should speed adoption even if it compresses unit economics. With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market
• Neutral Sentiment: Interest/attention indicators: NVO is a trending stock on investor screens — increased search and mention volume can amplify short‑term volatility but isn’t a fundamental read. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Competitive landscape: coverage notes heightened rivalry with Eli Lilly (new oral entrants and filings). Competition increases execution risk but also validates a large market. The Weight Loss Drug Competition Is Heating Up
• Negative Sentiment: Pricing pressure in China: Novo has cut Wegovy prices in some Chinese provinces — reports say prices were nearly halved in places as the company preempts generic competition; this raises near‑term revenue and margin risk in a large market. Novo cuts Wegovy prices in some Chinese provinces, local media reports Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat

Novo Nordisk A/S Trading Down 1.9%

NVO stock opened at $51.40 on Tuesday. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80. The stock has a market capitalization of $229.51 billion, a price-to-earnings ratio of 14.94 and a beta of 0.67. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The firm’s fifty day simple moving average is $49.27 and its two-hundred day simple moving average is $56.41.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 22nd. Jefferies Financial Group assumed coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an “underperform” rating on the stock. Morgan Stanley reissued an “underweight” rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Finally, Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and a consensus price target of $53.33.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.